RPRX
$45.36-0.17 (-0.37%)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-sta...
Recent News
How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations
Royalty Pharma’s updated fair value price target now sits at US$51.56, compared with the previous US$51.00 level. Analysts linking this shift to current Street commentary point to optimism around the royalty portfolio and deal structuring, while still flagging execution and deal flow as areas to watch. As you read on, you will see how these moving pieces feed into the evolving narrative and what to keep an eye on as sentiment changes. Stay updated as the Fair Value for Royalty Pharma shifts...
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
Cytokinetics (NASDAQ:CYTK) executives told investors at the Barclays healthcare conference that the company’s U.S. launch of MYQORZO is still in its earliest phase but showing what management described as encouraging initial signs, while a key phase 3 readout in non-obstructive hypertrophic cardiomy
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations
Royalty Pharma plc (NASDAQ:RPRX) is among the 11 Best Low Priced Growth Stocks to Buy Right Now. On February 12, Goldman Sachs raised its price target on Royalty Pharma plc (NASDAQ:RPRX) to $51 from $45 and maintained a Buy rating after strong Q4 results. The firm noted that portfolio receipts and 2026 guidance exceeded expectations, […]
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule
Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now. On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total portfolio receipts and an 18% jump in Q4 alone. The company achieved a notable 15.8% return on invested capital and successfully […]
Zymeworks Leans On Zanidatamab Results To Build Royalty Focused Model
Zymeworks (NasdaqGS:ZYME) reported positive Phase 3 results for partnered HER2 antibody zanidatamab. The company indicated it is working toward a potential U.S. approval and launch in the second half of 2026. Zymeworks entered a $250 million non recourse royalty backed note financing agreement with Royalty Pharma. The company is shifting to a hybrid business model focused on partnerships and a diversified royalty portfolio. Zymeworks also filed a shelf registration to keep options open for...